Clinical trial
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or…
NCT00033423 · University of Alabama at Birmingham, Other · Terminated
Key facts
| NCT number | NCT00033423 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | Phase I, Multicenter, Open Label, Dose Escalation Of 90Y-Zevalin Radioimmunotherapy Using A Modified Treatment Regimen For Relapsed Or Refractory CD20+ B-Cell (Follicular/Transformed) Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Radiation |
| Interventions | rituximab, yttrium Y 90 ibritumomab tiuxetan |
| Enrollment | 18 |
| Start date | Aug 1, 2001 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: